modelUrsodeoxycholicAcid
Extends from Pharmacolibrary.Drugs.ATC.A.A05AA02.
Information
| name: | UrsodeoxycholicAcid | |
| ATC code: | A05AA02 | route: | oral |
| compartments: | 1 | |
| dosage: | 250 | mg |
| volume of distribution: | 15.8 | L |
| clearance: | 3.3 | L/h |
| other parameters in model implementation | ||
Ursodeoxycholic acid (UDCA) is a secondary bile acid used for the treatment of primary biliary cholangitis (PBC) and certain cholestatic liver diseases. It works by reducing the absorption of cholesterol and protecting liver cells. It is an approved drug and remains the standard therapy for PBC and certain pediatric cholestatic conditions.
Pharmacokinetics
Pharmacokinetic parameters reported in healthy adult volunteers, both male and female, after single oral administration.
References
Yoon, S, et al., & Chung, JY (2021). Pharmacokinetics and Pharmacodynamics of Ursodeoxycholic Acid in an Overweight Population With Abnormal Liver Function. Clinical pharmacology in drug development 10(1) 68–77. DOI:10.1002/cpdd.790 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32191400
Zuo, P, et al., & Young, MA (2016). A Systems Model for Ursodeoxycholic Acid Metabolism in Healthy and Patients With Primary Biliary Cirrhosis. CPT: pharmacometrics & systems pharmacology 5(8) 418–426. DOI:10.1002/psp4.12100 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27537780
Gordi, T, et al., & Blood, AB (2014). Pharmacokinetic analysis of 14C-ursodiol in newborn infants using accelerator mass spectrometry. Journal of clinical pharmacology 54(9) 1031–1037. DOI:10.1002/jcph.327 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24805288
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)